Abstract: In certain embodiments, methods and compositions are provided for generating immune responses against tumor neo-antigens or neo-epitopes. In particular embodiments there may be provided methods for constructing and producing recombinant adenovirus-based vector vaccines containing nucleic acid sequences encoding tumor neo-antigens and neo-epitopes that allow for vaccinations in individuals with preexisting immunity to adenovirus. In additional embodiments, methods and compositions are provided for the treatment of cancer using immunotherapy based on recombinant adenovirus-based vectors combined with engineered natural killer cells. In some embodiments, the methods and compositions further comprises a nucleic acid encoding for an immunological fusion partner.

Abstract: Methods and compositions for generating enhanced immune responses using adenovirus vectors that encode for an antigen and calreticulin, which serves as an immunologic adjuvant.

Abstract: Methods for rapidly confirming production of infectious viral vectors, for use in clinical grade personalized neo-antigen vaccines for subjects in need thereof, are provided.

Abstract: Compositions of a recombinant adenovirus based vector vaccine containing one or more flavivirus antigen genes are disclosed herein. Methods for constructing and producing such vaccines and methods of using these vaccines to generate immune responses against flaviviruses are also described. Compositions described herein allow for vaccinations in subjects with preexisting immunity to adenovirus.

Abstract: In certain embodiments, methods and compositions are provided for generating immune responses against tumor neo-antigens or neo-epitopes. In particular embodiments there may be provided methods for constructing and producing recombinant adenovirus-based vector vaccines containing nucleic acid sequences encoding tumor neo-antigens and neo-epitopes that allow for vaccinations in individuals with preexisting immunity to adenovirus. In additional embodiments, methods and compositions are provided for the treatment of cancer using immunotherapy based on recombinant adenovirus-based vectors combined with engineered natural killer cells. In some embodiments, the methods and compositions further comprises a nucleic acid encoding for an immunological fusion partner.

Abstract: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.

Abstract: Methods for generating immune responses to Ebola virus antigens using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.

Abstract: Compositions of a recombinant adenovirus based vector vaccine containing one or more alphavirus antigen genes are disclosed herein. Methods for constructing and producing such vaccines and methods of using these vaccines to generate broad based immune responses against alphaviruses are also described. Compositions described herein allow for vaccinations in individuals with preexisting immunity to adenovirus.

Abstract: Compositions of a recombinant adenovirus based vector vaccine containing one or more flavivirus antigen genes are disclosed herein. Methods for constructing and producing such vaccines and methods of using these vaccines to generate immune responses against flaviviruses are also described. Compositions described herein allow for vaccinations in subjects with preexisting immunity to adenovirus.

Abstract: Methods and compositions for generating enhanced immune responses using adenovirus vectors that allow for multiple vaccinations in combination with an IL-15 superagonist complex in subjects in need thereof are provided.

Abstract: In certain embodiments, methods and compositions are provided for generating immune responses against tumor antigens such as antigens or epitopes of HER1, HER2/neu, HER3, HER4, or any combination thereof. In particular embodiments, there may be provided methods for constructing and producing recombinant adenovirus-based vector vaccines containing nucleic acid sequences encoding tumor antigens such as antigens or epitopes of HER1, HER2/neu, HER3, HER4, or any combination thereof, that allow for vaccinations in individuals with preexisting immunity to adenovirus.

Abstract: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.

Abstract: In certain embodiments, methods and compositions are provided for generating immune responses against tumor antigens such as a HER2/neu antigen or epitope. In particular embodiments there may be provided methods for constructing and producing recombinant adenovirus-based vector vaccines containing nucleic acid sequences encoding tumor antigens such as a HER2/neu antigen or epitope that allow for vaccinations in individuals with preexisting immunity to adenovirus.

Abstract: Methods and compositions for constructing and producing recombinant adenovirus-based vector vaccines are provided. In particular aspects, there are be provided compositions and methods involving adenovirus vectors comprising genes for target antigens, such as novel antigens of HPV E6 and/or HPV E7 for use in treatment methods that generate highly reactive anti-HPV and anti-tumor immune responses in subjects with preexisting immunity to adenovirus.

Abstract: Methods and compositions for constructing and producing recombinant adenovirus-based vector vaccines are provided. In particular aspects, there are be provided compositions and methods involving adenovirus vectors comprising genes for target antigens, such as pro state-specific antigen (PSA), pro state-specific membrane antigen (PSMA), MUC1, CEA, and/or Brachyury, and costimulatory molecules for use in treatment methods that generate highly reactive anti-tumor immune responses and that allows for multiple vaccinations in individuals with preexisting immunity to adenovirus.

Abstract: Genetically modified compositions, such as adenoviral vectors and T cells, for treating diseases such as cancer and infectious diseases are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating diseases such as cancer and infectious diseases.

Abstract: Methods for constructing and producing a recombinant adenovirus based vector vaccine containing multiple influenza antigen genes for use in generating broad based immune responses against influenza A and B viruses and that allows for multiple vaccinations in individuals with preexisting immunity to adenovirus are described. Specifically, the recombinant adenovirus based vector is a replication defective adenovirus vector comprising a deletion in an early 2b (E2b) gene.

Abstract: Methods and compositions for generating immune responses using adenovirus vectors that allow multiple vaccinations or in combination with other therapy and vaccinations in individuals with preexisting immunity to adenovirus are provided.

Abstract: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.

Abstract: Methods for generating immune responses to Ebola virus antigens using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.